Coagulation in patients with severe sepsis

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 1, 2015, Pages 9-15

  Levi, Marcel ^a   Poll, Tom Van Der ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

antithrombin; coagulation; fibrinolysis; inflammation; protein C; sepsis; tissue factor

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; FIBRIN; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTHROMBIN COMPLEX; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULANT THERAPY; ARTICLE; ASSISTED CIRCULATION; ASSISTED VENTILATION; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CONTROLLED CLINICAL TRIAL (TOPIC); DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DOWN REGULATION; HUMAN; INCIDENCE; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; THROMBOCYTE TRANSFUSION; UPREGULATION; ANIMAL; BLOOD; PHYSIOLOGY;

ANIMALS; BLOOD COAGULATION; HUMANS; SEPSIS;

EID: 84928489934     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1398376     Document Type: Article

References (76)

1. Wheeler A. P., Bernard G. R. Treating patients with severe sepsis. N Engl J Med: 1999; 340 3 207 214
2. Martin G. S., Mannino D. M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med: 2003; 348 16 1546 1554
3. Angus D. C., Linde-Zwirble W. T., Lidicker J., Clermont G., Carcillo J., Pinsky M. R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med: 2001; 29 7 1303 1310
4. Levi M., ten Cate H., van der Poll T., van Deventer S. J. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA: 1993; 270 8 975 979
5. Levi M. The coagulant response in sepsis. Clin Chest Med: 2008; 29 4 627 642, viii
6. Levi M., Ten Cate H. Disseminated intravascular coagulation. N Engl J Med: 1999; 341 8 586 592
7. Miller D. L., Welty-Wolf K., Carraway M. S., et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol: 2002; 26 6 650 658
8. Levi M., de Jonge E., van der Poll T., ten Cate H. Disseminated intravascular coagulation. Thromb Haemost: 1999; 82 2 695 705
9. Ratnoff O. D., Nebehay W. G. Multiple coagulative defects in a patient with the Waterhouse-Friderichsen syndrome. Ann Intern Med: 1962; 56 627 632
10. Levi M., de Jonge E., van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis: 2003; 16 1-2 43 47
11. Vanderschueren S., De Weerdt A., Malbrain M., et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med: 2000; 28 6 1871 1876
12. Strauss R., Wehler M., Mehler K., Kreutzer D., Koebnick C., Hahn E. G. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med: 2002; 30 8 1765 1771
13. Akca S., Haji-Michael P., de Mendonça A., Suter P., Levi M., Vincent J. L. Time course of platelet counts in critically ill patients. Crit Care Med: 2002; 30 4 753 756
14. Mavrommatis A. C., Theodoridis T., Orfanidou A., Roussos C., Christopoulou-Kokkinou V., Zakynthinos S. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med: 2000; 28 2 451 457
15. Folman C. C., Linthorst G. E., van Mourik J., et al. Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis? Thromb Haemost: 2000; 83 6 923 930
16. François B., Trimoreau F., Vignon P., Fixe P., Praloran V., Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med: 1997; 103 2 114 120
17. Warkentin T. E., Aird W. C., Rand J. H. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program: 2003; 497 519
18. MacLeod J. B., Lynn M., McKenney M. G., Cohn S. M., Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma: 2003; 55 1 39 44
19. Shorr A. F., Thomas S. J., Alkins S. A., Fitzpatrick T. M., Ling G. S. D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest: 2002; 121 4 1262 1268
20. Bernard G. R., Vincent J. L., Laterre P. F., et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med: 2001; 344 10 699 709
21. Gando S., Nanzaki S., Sasaki S., Kemmotsu O. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost: 1998; 79 6 1111 1115
22. Levi M., van der Poll T., ten Cate H., van Deventer S. J. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. [Review] [56 refs] Eur J Clin Invest: 1997; 27 1 3 9
23. Levi M., van der Poll T., Buller H. R. Bidirectional relation between inflammation and coagulation. Circulation: 2004; 109 22 2698 2704
24. Aird W. C. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med: 2001; 29 (7, Suppl): S28 S34; discussion S34-S35
25. Levi M., van der Poll T. Inflammation and coagulation. Crit Care Med: 2010; 38 (2, Suppl): S26 S34
26. Taylor F. BJ Jr, Chang A., Ruf W., et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock: 1991; 33 3 127 134
27. Levi M., ten Cate H., Bauer K. A., et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest: 1994; 93 1 114 120
28. Osterud B., Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost: 1983; 49 1 5 7
29. Franco R. F., de Jonge E., Dekkers P. E., et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood: 2000; 96 2 554 559
30. Giesen P. L., Rauch U., Bohrmann B., et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A: 1999; 96 5 2311 2315
31. Osterud B., Rao L. V., Olsen J. O. Induction of tissue factor expression in whole blood: lack of evidence for the presence of tissue factor expression in granulocytes. Thromb Haemost: 2000; 83 6 861 867
32. Rauch U., Bonderman D., Bohrmann B., et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood: 2000; 96 1 170 175
33. Zimmerman G. A., McIntyre T. M., Prescott S. M., Stafforini D. M. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med: 2002; 30 (5, Suppl): S294 S301
34. Shebuski R. J., Kilgore K. S. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther: 2002; 300 3 729 735
35. Biemond B. J., Levi M., Ten Cate H., et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond): 1995; 88 5 587 594
36. Hermans P. W., Hibberd M. L., Booy R., et al. Meningococcal Research Group. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet: 1999; 354 9178 556 560
37. Westendorp R. G., Hottenga J. J., Slagboom P. E. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet: 1999; 354 9178 561 563
38. Hinshaw L. B., Tekamp-Olson P., Chang A. C., et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock: 1990; 30 3 279 292
39. Abraham E., Wunderink R., Silverman H., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA: 1995; 273 12 934 941
40. van der Poll T., Levi M., Hack C. E., et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med: 1994; 179 4 1253 1259
41. Stouthard J. M., Levi M., Hack C. E., et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost: 1996; 76 5 738 742
42. Boermeester M. A., van Leeuwen P. A., Coyle S. M., Wolbink G. J., Hack C. E., Lowry S. F. Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg: 1995; 130 7 739 748
43. Coughlin S. R. Thrombin signalling and protease-activated receptors. Nature: 2000; 407 6801 258 264
44. Kaneider N. C., Förster E., Mosheimer B., Sturn D. H., Wiedermann C. J. Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost: 2003; 90 6 1150 1157
45. Esmon C. T. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med: 2002; 196 5 561 564
46. Yuksel M., Okajima K., Uchiba M., Horiuchi S., Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost: 2002; 88 2 267 273
47. Murakami K., Okajima K., Uchiba M., et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood: 1996; 87 2 642 647
48. Taylor F. BJ Jr, Stearns-Kurosawa D. J., Kurosawa S., et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood: 2000; 95 5 1680 1686
49. Levi M., Dörffler-Melly J., Reitsma P., et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood: 2003; 101 12 4823 4827
50. Baughman R. P., Lower E. E., Flessa H. C., Tollerud D. J. Thrombocytopenia in the intensive care unit. Chest: 1993; 104 4 1243 1247
51. Levi M., de Jonge E., Meijers J. The diagnosis of disseminated intravascular coagulation. Blood Rev: 2002; 16 4 217 223
52. Levi M., Toh C. H., Thachil J., Watson H. G.; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol: 2009; 145 1 24 33
53. Dempfle C. E., Pfitzner S. A., Dollman M., Huck K., Stehle G., Heene D. L. Comparison of immunological and functional assays for measurement of soluble fibrin. Thromb Haemost: 1995; 74 2 673 679
54. McCarron B. I., Marder V. J., Kanouse J. J., Francis C. W. A soluble fibrin standard: comparable dose-response with immunologic and functional assays. Thromb Haemost: 1999; 82 1 145 148
55. Dempfle C. E. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost: 1999; 82 2 673 683
56. Horan J. T., Francis C. W. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost: 2001; 27 6 657 666
57. Carr J. M., McKinney M., McDonagh J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer. Am J Clin Pathol: 1989; 91 3 280 287
58. Prisco D., Paniccia R., Bonechi F., Francalanci I., Abbate R., Gensini G. F. Evaluation of new methods for the selective measurement of fibrin and fibrinogen degradation products. Thromb Res: 1989; 56 4 547 551
59. Shorr A. F., Trotta R. F., Alkins S. A., Hanzel G. S., Diehl L. F. D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease. Intensive Care Med: 1999; 25 2 207 210
60. Bick R. L. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin Thromb Hemost: 1996; 22 1 69 88
61. Levi M., Meijers J. C. DIC: which laboratory tests are most useful. Blood Rev: 2011; 25 1 33 37
62. Dempfle C. E., Borggrefe M. Point of care coagulation tests in critically ill patients. Semin Thromb Hemost: 2008; 34 5 445 450
63. Johansson P. I., Stensballe J., Vindelov N., Perner A., Espersen K. Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality. Blood Coagul Fibrinolysis: 2010; 21 2 168 174
64. Park M. S., Martini W. Z., Dubick M. A., et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma: 2009; 67 2 266 275, discussion 275-276
65. Collins P. W., Macchiavello L. I., Lewis S. J., et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol: 2006; 135 2 220 227
66. Taylor F. BJ Jr, Toh C. H., Hoots W. K., Wada H., Levi M.; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost: 2001; 86 5 1327 1330
67. Bakhtiari K., Meijers J. C., de Jonge E., Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med: 2004; 32 12 2416 2421
68. Toh C. H., Hoots W. K.; SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost: 2007; 5 3 604 606
69. Dhainaut J. F., Yan S. B., Joyce D. E., et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost: 2004; 2 11 1924 1933
70. Levi M. Settling the score for disseminated intravascular coagulation. Crit Care Med: 2005; 33 10 2417 2418
71. Alving B. M., Spivak J. L., DeLoughery T. G. Consultative hematology: Hemostasis and transfusion issues in surgery and critical care medicine. In: McArthur J. R., Schechter G. P., Schrier S. L., eds. Hematology 1998. The American Society of Hematology Education Program Book: 1998; 320 341
72. de Jonge E., Levi M., Stoutenbeek C. P., van Deventer S. J. Current drug treatment strategies for disseminated intravascular coagulation. Drugs: 1998; 55 6 767 777
73. du Toit H. J., Coetzee A. R., Chalton D. O. Heparin treatment in thrombin-induced disseminated intravascular coagulation in the baboon. Crit Care Med: 1991; 19 9 1195 1200
74. Feinstein D. I. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood: 1982; 60 2 284 287
75. Dörffler-Melly J., de Jonge E., Pont A. C., et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet: 2002; 359 9309 849 850
76. Levi M., van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost: 2008; 34 5 459 468